Contribute Try STAT+ Today

WASHINGTON — The Biotechnology Innovation Organization, the lobbying group that represents roughly 1,000 biotech companies, is wrestling with inner turmoil that threatens its ability to navigate a Washington that is eager to reform drug prices.

Five of the organization’s top lobbyists have left within the last eight months, including the executive who led the organization’s policy and legal work for more than a decade. This month, BIO announced that its longtime head of lobbying, Jeanne Haggerty, was departing — a move that shocked staff and member company lobbyists who worked directly with Haggerty. Less than a week later, BIO announced her replacement.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment